These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 1156561)

  • 21. Disk diffusion testing with polymyxin and amikacin for differentiation of Mycobacterium fortuitum and Mycobacterium chelonei.
    Wallace RJ; Swenson JM; Silcox VA; Good RC
    J Clin Microbiol; 1982 Dec; 16(6):1003-6. PubMed ID: 6298271
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapid growing mycobacteria and TNF-α blockers: case report of a fatal lung infection with Mycobacterium abscessus in a patient treated with infliximab, and literature review.
    Besada E
    Clin Exp Rheumatol; 2011; 29(4):705-7. PubMed ID: 21906433
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Resistant cutaneous infection caused by Mycobacterium chelonei.
    Fenske NA; Millns JL
    Arch Dermatol; 1981 Mar; 117(3):151-3. PubMed ID: 7212728
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro susceptiiblity of Mycobacterium fortuitum and Mycobacterium chelonei to amikacin.
    Dalovisio JR; Pankey GA
    J Infect Dis; 1978 Mar; 137(3):318-21. PubMed ID: 632627
    [TBL] [Abstract][Full Text] [Related]  

  • 25. General characteristics, features of cultivation and antibiotic resistance representatives of mycobacterium fortuitum group representatives (review of literature).
    Gerasimova EN; Ismatullin DD; Lyamin AV; Zhestkov AV
    Klin Lab Diagn; 2021 Apr; 66(4):223-228. PubMed ID: 33878244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ALA-PDT combined with antibiotics for the treatment of multiple skin abscesses caused by Mycobacterium fortuitum.
    Gong N; Tan Y; Li M; Lu W; Lei X
    Photodiagnosis Photodyn Ther; 2016 Sep; 15():70-2. PubMed ID: 27235279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differentiation of Mycobacterium chelonei from M. fortuitum by ciprofloxacin susceptibility.
    Collins CH; Yates MD; Uttley AH
    J Hyg (Lond); 1985 Dec; 95(3):619-21. PubMed ID: 2936800
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Skin and wound infection by rapidly growing mycobacteria: an unexpected complication of liposuction and liposculpture. The Venezuelan Collaborative Infectious and Tropical Diseases Study Group.
    Murillo J; Torres J; Bofill L; Ríos-Fabra A; Irausquin E; Istúriz R; Guzmán M; Castro J; Rubino L; Cordido M
    Arch Dermatol; 2000 Nov; 136(11):1347-52. PubMed ID: 11074697
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two outbreaks of sternal wound infection due to organisms of the Mycobacterium fortuitum complex.
    Hoffman PC; Fraser DW; Robicsek F; O'Bar PR; Mauney CU
    J Infect Dis; 1981 Apr; 143(4):533-42. PubMed ID: 7240799
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug Susceptibility Testing of 31 Antimicrobial Agents on Rapidly Growing Mycobacteria Isolates from China.
    Pang H; Li G; Zhao X; Liu H; Wan K; Yu P
    Biomed Res Int; 2015; 2015():419392. PubMed ID: 26351633
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Host immune response to rapidly growing mycobacteria, an emerging cause of chronic lung disease.
    Chan ED; Bai X; Kartalija M; Orme IM; Ordway DJ
    Am J Respir Cell Mol Biol; 2010 Oct; 43(4):387-93. PubMed ID: 20081053
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enzymatic and immunological characterization of the Mycobacterium fortuitum complex.
    Binko BP; Bartholomew WR
    J Clin Microbiol; 1978 Aug; 8(2):246-51. PubMed ID: 100510
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nontuberculous mycobacterial infections of the skin: A retrospective study of 25 cases.
    Dodiuk-Gad R; Dyachenko P; Ziv M; Shani-Adir A; Oren Y; Mendelovici S; Shafer J; Chazan B; Raz R; Keness Y; Rozenman D
    J Am Acad Dermatol; 2007 Sep; 57(3):413-20. PubMed ID: 17368631
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Growth of group IV mycobacteria on medium containing various saturated and unsaturated fatty acids.
    Saito H; Tomioka H; Yoneyama T
    Antimicrob Agents Chemother; 1984 Aug; 26(2):164-9. PubMed ID: 6486760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An injection abscess due to
    Singh S; Kombade SP; Khan S; Samaddar A; Kalita JM; Nag VL
    J Family Med Prim Care; 2020 May; 9(5):2573-2576. PubMed ID: 32754550
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multifocal osteomyelitis caused by Mycobacterium chelonei. A therapeutic dilemma.
    Hing DC; Delohery JF; Abbott MR
    Med J Aust; 1983 May; 1(11):529-31. PubMed ID: 6843447
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mycobacterium chelonei iatrogenic infections.
    Foz A; Roy C; Jurado J; Arteaga E; Ruiz JM; Moragas A
    J Clin Microbiol; 1978 Mar; 7(3):319-21. PubMed ID: 77278
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Susceptibility to antimicrobial agents of rapidly growing mycobacteria].
    Ruiz-Aragón J; García-Agudo L; Flores S; Rodríguez MJ; Marín P; García-Martos P
    Rev Esp Quimioter; 2007 Dec; 20(4):429-32. PubMed ID: 18563216
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cases of Mycobacterium borstelense and M. abscessus infection observed in Belgium.
    Pattyn SR; Vandepitte J; Portaels F; De Muynck A
    J Med Microbiol; 1971 Feb; 4(1):145-9. PubMed ID: 5548599
    [No Abstract]   [Full Text] [Related]  

  • 40. Evaluation of antimicrobial susceptibilities of rapidly growing mycobacteria by Sensititre RAPMYCO panel.
    Cavusoglu C; Gurpinar T; Ecemis T
    New Microbiol; 2012 Jan; 35(1):73-6. PubMed ID: 22378556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.